Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: sub-study of the HERO trial
Author: Zhang, L.
Coombes, J.
Pascoe, E.
Badve, S.
Dalziel, K.
Cass, A.
Clarke, P.
Ferrari, P.
McDonald, S.
Morrish, A.
Pedagogos, E.
Perkovic, V.
Reidlinger, D.
Scaria, A.
Walker, R.
Vergara, L.
Hawley, C.
Johnson, D.
Citation: Redox Report, 2016; 21(1):14-23
Publisher: Taylor & Francis
Issue Date: 2016
ISSN: 1351-0002
Statement of
Lei Zhang, Jeff Coombes, Elaine M. Pascoe, Sunil V. Badve, Kim Dalziel, Alan Cass, Philip Clarke, Paolo Ferrari, Stephen P. McDonald, Alicia T. Morrish, Eugenie Pedagogos, Vlado Perkovic, Donna Reidlinger, Anish Scaria, Rowan Walker, Liza A. Vergara, Carmel M. Hawley, David W. Johnson (on behalf of the HERO Study Collaborative Group)
Abstract: Objective: Pentoxifylline has previously been shown to increase haemoglobin levels in patients with chronic kidney disease (CKD) and erythropoietin-stimulating agent (ESA)-hyporesponsive anaemia in the HERO multi-centre double-blind, randomized controlled trial. The present study evaluated the effects of pentoxifylline on oxidative stress in ESA-hyporesponsive CKD patients. Methods: This sub-study of the HERO trial compared 15 patients in the pentoxifylline arm (400 mg daily) and 17 in the matched placebo arm on oxidative stress markers: plasma total F2-isoprostanes, protein carbonyls, glutathione peroxidase (GPX), and superoxide dismutase (SOD) activities. Results: Pentoxifylline did not significantly alter total F2-isoprostanes (adjusted mean difference (MD) 35.01 pg/ml, P = 0.11), SOD activity (MD 0.82 U/ml, P = 0.07), GPX activity (MD −6.06 U/l, P = 0.09), or protein carbonyls (MD −0.04 nmol/mg, P = 0.52). Replicating results from the main study, pentoxifylline significantly increased haemoglobin concentration compared with controls (MD 7.2 g/l, P=0.04). Conclusions: Pentoxifylline did not alter oxidative stress biomarkers, suggesting that alternative mechanisms may be responsible for the agent’s ability to augment haemoglobin levels in CKD patients with ESA-hyporesponsive anaemia.
Keywords: Anaemia; chronic kidney disease; erythropoiesis-stimulating agent; oxidative stress; pentoxifylline
Rights: © 2016 Informa UK Limited, trading as Taylor & Francis Group
DOI: 10.1179/1351000215Y.0000000022
Published version:
Appears in Collections:Aurora harvest 7
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.